<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SF ROWASA- mesalamine suspension </strong><br>Alaven Pharmaceutical LLC<br></p></div>
<h1>sfROWASA™ <br>(mesalamine) <br>Rectal Suspension <br>4g/60ml <br>Sulfite-Free Formulation</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx</span> only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The active ingredient in sfROWASA™ (mesalamine) Rectal Suspension, a disposable (60 mL) unit, is mesalamine, also known as 5-aminosalicylic acid (5-ASA). Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid.</p>
<p>The empirical formula is C<span class="Sub">7</span>H<span class="Sub">7</span>NO<span class="Sub">3</span>, representing a molecular weight of 153.14. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-01.jpg"></div>
<p>Each rectal suspension unit contains 4 grams of mesalamine. In addition to mesalamine the preparation contains the inactive ingredients carbomer 934P, edetate disodium, potassium acetate, purified water, sodium benzoate, and xanthan gum. Sodium benzoate is added as a preservative. The disposable unit consists of an applicator tip protected by a polyethylene cover and lubricated with USP white petrolatum. The unit has a one-way valve to prevent back flow of the dispensed product.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component is therapeutically active in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> [A.K. Azad Khan et al, Lancet 2:892-895 (1977)]. The usual oral dose of sulfasalazine for active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in adults is two to four grams per day in divided doses. Four grams of sulfasalazine provide 1.6 g of free mesalamine to the colon. Each sfROWASA™ (mesalamine) Rectal Suspension delivers up to 4 g of mesalamine to the left side of the colon.</p>
<p>The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs) is increased in patients with chronic <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, and it is possible that mesalamine diminishes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Preclinical Toxicology</h2>
<p class="First">Preclinical studies have shown the kidney to be the major target organ for mesalamine toxicity. Adverse renal function changes were observed in rats after a single 600 mg/kg oral dose, but not after a 200 mg/kg dose. Gross kidney lesions, including papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, were observed after a single oral &gt;900 mg/kg dose, and after I.V. doses of &gt;214 mg/kg. Mice responded similarly. In a 13-week oral (gavage) dose study in rats, the high dose of 640 mg/kg/day mesalamine caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, probably due to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and dose-related renal lesions (papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and/or multifocal tubular injury) were seen in most rats given the high dose (males and females) as well as in males receiving lower doses 160 mg/kg/day. Renal lesions were not observed in the 160 mg/kg/day female rats. Minimal tubular epithelial damage was seen in the 40 mg/kg/day males and was reversible. In a six-month oral study in dogs, the no-observable dose level of mesalamine was 40 mg/kg/day and doses of 80 mg/kg/day and higher caused renal pathology similar to that described for the rat. In a combined 52-week toxicity and 127-week carcinogenicity study in rats, degeneration in kidneys was observed at doses of 100 mg/kg/day and above admixed with diet for 52 weeks, and at 127 weeks increased incidence of kidney degeneration and hyalinization of basement membranes and Bowman's capsule were seen at 100 mg/kg/day and above. In the 12-month eye toxicity study in dogs, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Keratoconjunctivitis Sicca</span> (KCS) occurred at oral doses of 40 mg/kg/day and above. The oral preclinical studies were done with a highly bioavailable suspension where absorption throughout the gastrointestinal tract occurred. The human dose of 4 grams represents approximately 80 mg/kg but when mesalamine is given rectally as a suspension, absorption is poor and limited to the distal colon (see <a href="#Pharmacokinetics">Pharmacokinetics</a>). Overt renal toxicity has not been observed (see <a href="#AR">ADVERSE REACTIONS</a> and <a href="#PRECAUTIONS">PRECAUTIONS</a>), but the potential must be considered.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Mesalamine administered rectally is poorly absorbed from the colon and is excreted principally in the feces during subsequent bowel movements. The extent of absorption is dependent upon the retention time of the drug product, and there is considerable individual variation. At steady state, approximately 10 to 30% of the daily 4 grams dose can be recovered in cumulative 24-hour urine collections. Other than the kidney, the organ distribution and other bioavailability characteristics of absorbed mesalamine in man are not known. It is known that the compound undergoes acetylation but whether this process takes place at colonic or systemic sites has not been elucidated.</p>
<p>Whatever the metabolic site, most of the absorbed mesalamine is excreted in the urine as the N-acetyl-5-ASA metabolite. The poor colonic absorption of rectally administered mesalamine is substantiated by the low serum concentration of 5-ASA and N-acetyl-5-ASA seen in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients after dosage with mesalamine. Under clinical conditions patients demonstrated plasma levels 10 to 12 hours post mesalamine administration of 2 μg/mL, about two-thirds of which was the N-acetyl metabolite. While the elimination half-life of mesalamine is short (0.5 to 1.5 h), the acetylated metabolite exhibits a half-life of 5 to 10 hours [U. Klotz, Clin. Pharmacokin. 10:285-302 (1985)]. In addition, steady state plasma levels demonstrated a lack of accumulation of either free or metabolized drug during repeated daily administrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Efficacy</h2>
<p class="First">In a placebo-controlled, international, multicenter trial of 153 patients with active distal <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, proctosigmoiditis or <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, **sfROWASA™ (mesalamine) Rectal Suspension reduced the overall disease activity index (DAI) and individual components as follows:</p>
<table width="100%">
<caption><span>EFFECT OF TREATMENT ON SEVERITY OF DISEASE DATA FROM U.S.-CANADA TRIAL COMBINED RESULTS OF EIGHT CENTERS Activity Indices, mean</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="21%">
<col align="left" valign="top" width="7%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left"></th>
<th align="left" valign="bottom">N</th>
<th align="left" valign="bottom">Baseline</th>
<th align="left" valign="bottom">Day 22</th>
<th align="left" valign="bottom">End Point</th>
<th align="left" valign="bottom">Change Baseline to End Point<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">Each parameter has a 4-point scale with a numerical rating:<br>0 = normal, 1 = mild, 2 = moderate, 3 = severe. The four parameters are added together to produce a maximum overall DAI of 12.</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Percent change for overall DAI only (calculated by taking the average of the change for each individual patient).</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Significant **sfROWASA™/placebo difference. p &lt; 0.01</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Significant **sfROWASA™/placebo difference. p &lt; 0.001</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Significant **sfROWASA™/placebo difference. p &lt; 0.05</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Overall DAI</td>
<td align="left">**sfROWASA™</td>
<td align="left">76</td>
<td align="left">7.42</td>
<td align="left">4.05<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">3.37<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="left">-55.07%<a href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="left">Placebo</td>
<td align="left">77</td>
<td align="left">7.40</td>
<td align="left">6.03</td>
<td align="left">5.83</td>
<td align="left">-21.58%</td>
</tr>
<tr>
<td align="left">Stool</td>
<td align="left">**sfROWASA™</td>
<td align="left"></td>
<td align="left">1.58</td>
<td align="left">1.11<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="left">1.01<a href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">-0.57<a href="#footnote-4" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Frequency</td>
<td align="left">Placebo</td>
<td align="left"></td>
<td align="left">1.92</td>
<td align="left">1.47</td>
<td align="left">1.50</td>
<td align="left">-0.41</td>
</tr>
<tr>
<td align="left">Rectal</td>
<td align="left">**sfROWASA™</td>
<td align="left"></td>
<td align="left">1.82</td>
<td align="left">0.59<a href="#footnote-3" class="Sup">‡</a>
</td>
<td align="left">0.51<a href="#footnote-3" class="Sup">‡</a>
</td>
<td align="left">-1.30<a href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
<td align="left">Placebo</td>
<td align="left"></td>
<td align="left">1.73</td>
<td align="left">1.21</td>
<td align="left">1.11</td>
<td align="left">-0.61</td>
</tr>
<tr>
<td align="left">Mucosal</td>
<td align="left">**sfROWASA™</td>
<td align="left"></td>
<td align="left">2.17</td>
<td align="left">1.22<a href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">0.96<a href="#footnote-3" class="Sup">‡</a>
</td>
<td align="left">-1.21<a href="#footnote-2" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></td>
<td align="left">Placebo</td>
<td align="left"></td>
<td align="left">2.18</td>
<td align="left">1.74</td>
<td align="left">1.61</td>
<td align="left">-0.56</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" rowspan="2">Physician's Assessment of Disease Severity</td>
<td align="left">**sfROWASA™<br>Placebo</td>
<td align="left"></td>
<td align="left">1.86<br>1.87</td>
<td align="left">1.13<a href="#footnote-3" class="Sup">‡</a><br>1.62
											</td>
<td align="left">0.88<a href="#footnote-3" class="Sup">‡</a><br>1.55
											</td>
<td align="left">-0.97<a href="#footnote-3" class="Sup">‡</a><br>-0.30
											</td>
</tr>
</tbody>
</table>
<p>Differences between **sfROWASA™ (mesalamine) Rectal Suspension and placebo were also statistically different in subgroups of patients on concurrent sulfasalazine and in those having an upper disease boundary between 5 and 20 or 20 and 40 cm. Significant differences between **sfROWASA™ (mesalamine) Rectal Suspension and placebo were not achieved in those subgroups of patients on concurrent prednisone or with an upper disease boundary between 40 and 50 cm.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">sfROWASA™ (mesalamine) Rectal Suspension is indicated for the treatment of active mild to moderate distal <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, proctosigmoiditis or <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">sfROWASA™ (mesalamine) Rectal Suspension is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any component of this medication.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, sometimes <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; in such cases prompt withdrawal is required. The patient's history of sulfasalazine intolerance, if any, should be re-evaluated. If a rechallenge is performed later in order to validate the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> it should be carried out under close supervision and only if clearly needed, giving consideration to reduced dosage. In the literature one patient previously sensitive to sulfasalazine was rechallenged with 400 mg oral mesalamine; within eight hours she experienced <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, intensive <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal colic</span>, profuse <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and was readmitted as an emergency. She responded poorly to steroid therapy and two weeks later a pancolectomy was required.</p>
<p>Although renal abnormalities were not noted in the clinical trials with **sfROWASA™ (mesalamine) Rectal Suspension, the possibility of increased absorption of mesalamine and concomitant renal tubular damage as noted in the preclinical studies must be kept in mind. Patients on sfROWASA™ (mesalamine) Rectal Suspension, especially those on concurrent oral products which liberate mesalamine and those with preexisting <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, should be carefully monitored with urinalysis, BUN (blood urea nitrogen), and creatinine studies.</p>
<p>In a clinical trial most patients who were hypersensitive to sulfasalazine were able to take mesalamine without evidence of any <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Nevertheless, caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine. These patients should be instructed to discontinue therapy if signs of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> become apparent.</p>
<p>While using **sfROWASA™ (mesalamine) Rectal Suspension, some patients have developed <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">pancolitis</span>. However, extension of upper disease boundary and/or flare-ups occurred less often in the ** ™ (mesalamine) Rectal Suspension treated group than in the placebo-treated group.</p>
<p>Worsening of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, including <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, may occur after commencing mesalamine.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> have been reported with mesalamine containing products including sulfasalazine. Cases of <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> have also been reported as manifestations of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>. In the cases reported with **sfROWASA™ (mesalamine) Rectal Suspension, there have been positive rechallenges with mesalamine or mesalamine containing products. In one of these cases, however, a second rechallenge with sulfasalazine was negative throughout a 2-month follow-up. <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> in patients treated with **sfROWASA™ (mesalamine) Rectal Suspension should be investigated with this information in mind. Discontinuation of sfROWASA™ (mesalamine) Rectal Suspension may be warranted in some cases, but rechallenge with mesalamine can be performed under careful clinical observation should the continued therapeutic need for mesalamine be present.</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Mesalamine caused no increase in the incidence of neoplastic lesions over controls in a 2-year study of Wistar rats fed up to 320 mg/kg/day of mesalamine admixed with diet. Mesalamine is not mutagenic to <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA98, TA100, TA1535, TA1537, TA1538. There were no reverse mutations in an assay using E. coli <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2UVRA. There were no effects in an in vivo mouse micronucleus assay at 600 mg/kg and in an in vivo sister chromatid exchange at doses up to 610 mg/kg. No effects on fertility were observed in rats receiving up to 320 mg/kg/day. The <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> in men associated with sulfasalazine has very rarely been reported among patients treated with mesalamine.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.2"></a><p></p>
<h2>Pregnancy (Category B)</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.2.1"></a><p></p>
<p class="First">Teratologic studies have been performed in rats and rabbits at oral doses up to five and eight times respectively, the maximum recommended human dose, and have revealed no evidence of harm to the embryo or the fetus. There are, however, no adequate and well-controlled studies in pregnant women for either sulfasalazine or 5-ASA. Because animal reproduction studies are not always predictive of human response, 5-ASA should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.3"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether mesalamine or its metabolite(s) are excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Clinical Adverse Experience</h2>
<p class="First">**sfROWASA™ (mesalamine) Rectal Suspension is usually well tolerated. Most adverse effects have been mild and transient.</p>
<table width="100%">
<caption><span>ADVERSE REACTIONS OCCURRING IN MORE THAN O.1% OF **sfROWASA™ (MESALAMINE) RECTAL SUSPENSION TREATED PATIENTS (COMPARISON TO PLACEBO)</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="left" colspan="2">**sfROWASA™</th>
<th align="left" colspan="2">PLACEBO</th>
</tr>
<tr>
<th align="left"></th>
<th align="left" colspan="2">N = 815</th>
<th align="left" colspan="2">N = 128</th>
</tr>
<tr class="Last">
<th align="left">SYMPTOM</th>
<th align="left">N</th>
<th align="left">%</th>
<th align="left">N</th>
<th align="left">%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span></td>
<td align="left">66</td>
<td align="left">8.10</td>
<td align="left">10</td>
<td align="left">  7.81</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">53</td>
<td align="left">6.50</td>
<td align="left">16</td>
<td align="left">12.50</td>
</tr>
<tr>
<td align="left">Gas/<span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="left">50</td>
<td align="left">6.13</td>
<td align="left">  5</td>
<td align="left">  3.91</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">47</td>
<td align="left">5.77</td>
<td align="left">12</td>
<td align="left">  9.38</td>
</tr>
<tr>
<td align="left">Flu</td>
<td align="left">43</td>
<td align="left">5.28</td>
<td align="left">  1</td>
<td align="left">  0.78</td>
</tr>
<tr>
<td align="left">Tired/Weak/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left">28</td>
<td align="left">3.44</td>
<td align="left">  8</td>
<td align="left">  6.25</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="left">26</td>
<td align="left">3.19</td>
<td align="left">  0</td>
<td align="left">  0.00</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/Spots</td>
<td align="left">23</td>
<td align="left">2.82</td>
<td align="left">  4</td>
<td align="left">  3.12</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span>/<span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span></td>
<td align="left">19</td>
<td align="left">2.33</td>
<td align="left">  9</td>
<td align="left">  7.03</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">17</td>
<td align="left">2.09</td>
<td align="left">  5</td>
<td align="left">  3.91</td>
</tr>
<tr>
<td align="left">Leg/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span></td>
<td align="left">17</td>
<td align="left">2.09</td>
<td align="left">  1</td>
<td align="left">  0.78</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left">15</td>
<td align="left">1.84</td>
<td align="left">  3</td>
<td align="left">  2.34</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span></td>
<td align="left">12</td>
<td align="left">1.47</td>
<td align="left">  2</td>
<td align="left">  1.56</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="left">11</td>
<td align="left">1.35</td>
<td align="left">  1</td>
<td align="left">  0.78</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> on Insertion of Tip</td>
<td align="left">11</td>
<td align="left">1.35</td>
<td align="left">  1</td>
<td align="left">  0.78</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td align="left">11</td>
<td align="left">1.35</td>
<td align="left">  0</td>
<td align="left">  0.00</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td align="left">10</td>
<td align="left">1.23</td>
<td align="left">  1</td>
<td align="left">  0.78</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">Rectal Pain</span></td>
<td align="left">10</td>
<td align="left">1.23</td>
<td align="left">  0</td>
<td align="left">  0.00</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="left">  8</td>
<td align="left">0.98</td>
<td align="left">  4</td>
<td align="left">  3.12</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair Loss</span></td>
<td align="left">  7</td>
<td align="left">0.86</td>
<td align="left">  0</td>
<td align="left">  0.00</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
<td align="left">  5</td>
<td align="left">0.61</td>
<td align="left">11</td>
<td align="left">  8.59</td>
</tr>
<tr>
<td align="left">UTI/Urinary Burning</td>
<td align="left">  5</td>
<td align="left">0.61</td>
<td align="left">  4</td>
<td align="left">  3.12</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">Rectal Pain</span>/Soreness/Burning</td>
<td align="left">  5</td>
<td align="left">0.61</td>
<td align="left">  3</td>
<td align="left">  2.34</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="left">  1</td>
<td align="left">0.12</td>
<td align="left">  4</td>
<td align="left">  3.12</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="left">  1</td>
<td align="left">0.12</td>
<td align="left">  3</td>
<td align="left">  2.34</td>
</tr>
</tbody>
</table>
<p>In addition, the following adverse events have been identified during post-approval use of products which contain (or are metabolized to) mesalamine in clinical practice: <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4025168" conceptname="Diffuse interstitial pulmonary fibrosis">fibrosing alveolitis</span> and elevated liver enzymes. Cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="4025168" conceptname="Diffuse interstitial pulmonary fibrosis">fibrosing alveolitis</span> have been reported as manifestations of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> as well. Published case reports and/or spontaneous post marketing surveillance have described rare instances of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>, and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> in men. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> can be part of the clinical presentation of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair Loss</span></h2>
<p class="First">Mild <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> characterized by "more hair in the comb" but no withdrawal from clinical trials has been observed in 7 of 815 mesalamine patients but none of the placebo-treated patients. In the literature there are at least six additional patients with mild <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> who received either mesalamine or sulfasalazine. Retreatment is not always associated with repeated <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dosage of sfROWASA™ (mesalamine) Rectal Suspension in 60 mL units is one rectal instillation (4.0 grams) once a day, preferably at bedtime, and retained for approximately eight hours. While the effect of sfROWASA™ (mesalamine) Rectal Suspension may be seen within 3 to 21 days, the usual course of therapy would be from 3 to 6 weeks depending on symptoms and sigmoidoscopic findings. Studies available to date have not assessed if sfROWASA™ (mesalamine) Rectal Suspension will modify relapse rates after the 6-week short-term treatment. sfROWASA™ (mesalamine) Rectal Suspension is for rectal use only.</p>
<p>Patients should be instructed to shake the bottle well to make sure the suspension is homogeneous. The patient should remove the protective sheath from the applicator tip. Holding the bottle at the neck will not cause any of the medication to be discharged. The position most often used is obtained by lying on the left side (to facilitate migration into the sigmoid colon); with the lower leg extended and the upper right leg flexed forward for balance. An alternative is the knee-chest position. The applicator tip should be gently inserted in the rectum pointing toward the umbilicus. A steady squeezing of the bottle will discharge most of the preparation. The preparation should be taken at bedtime with the objective of retaining it all night. Patient instructions are included with every seven units.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">sfROWASA™ (mesalamine) Rectal Suspension for rectal administration is an off-white to tan colored suspension. Each disposable bottle contains 4.0 grams of mesalamine in 60 mL aqueous suspension. Bottles are supplied in boxed, foil-wrapped trays as follows:.</p>
<table width="50%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">NDC 68220-022-01</td>
<td align="left">Sample - 1 bottle</td>
</tr>
<tr>
<td align="left">NDC 68220-022-07</td>
<td align="left">Carton of 7 Bottles</td>
</tr>
<tr>
<td align="left">NDC 68220-022-14</td>
<td align="left">Carton of 14 Bottles</td>
</tr>
<tr class="Botrule Last">
<td align="left">NDC 68220-022-28</td>
<td align="left">Carton of 28 Bottles</td>
</tr>
</tbody>
</table>
<p>sfROWASA™ (mesalamine) Rectal Suspension is for rectal use only.</p>
<p>KEEP OUT OF REACH OF CHILDREN</p>
<p>Patient instructions are included.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted, please refer to current USP. Once the foil-wrapped unit of seven bottles is opened, any bottles remaining after 14 days should be discarded. Contents of product removed from the foil pouch may darken with time. Slight darkening will not affect potency, however, product with dark brown contents should be discarded.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First">** Clinical studies were performed using Rowasa<span class="Sup">®</span> (mesalamine) Rectal Suspension Enema, 4g/60mL, the original formulation, which contains the ingredient potassium metabisulfite.</p>
<p>NOTE: sfROWASA™ (mesalamine) Rectal Suspension will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel. Take care in choosing a suitable location for administration of this product.</p>
<p><span class="Bold">Rx</span> only</p>
<p>Rev. 06/08<br>© ALAVEN<span class="Sup">®</span> Pharmaceutical LLC<br>www.sfROWASA.com</p>
<p>Manufactured For:<br><span class="Bold">Alaven<span class="Sup">®</span> Pharmaceutical LLC</span><br>2260 Northwest Parkway, Suite A<br>Marietta, GA 30067</p>
<p>For Medical Inquiries, Call Toll Free:<br>1-888-317-0001</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-12"></a><p></p>
<h1>PATIENT INSTRUCTIONS</h1>
<p class="First">How to Use this Medication.</p>
<p><span class="Bold">Best results are achieved if the bowel is emptied immediately before the medication is given.</span></p>
<p><span class="Bold">Use as prescribed by your physician.</span></p>
<p><span class="Bold">Do not consume the Oxygen Scavenger Pack included in the foil pouch.</span></p>
<p><span class="Bold">NOTE: sfROWASA™ (mesalamine) Rectal Suspension will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel. Take care in choosing a suitable location for administration of this product.</span></p>
<p><span class="Bold">1 Remove the Bottles</span></p>
<ol class="LittleAlpha"><li>Remove the bottles from the protective foil pouch by tearing or by using scissors as shown, being careful not to squeeze or puncture bottles. sfROWASA™ (mesalamine) Rectal Suspension is an off-white to tan colored suspension. Once the foil-wrapped unit of seven bottles is opened, any bottles remaining after 14 days should be discarded.<br> <br><span class="Bold">Contents of product removed from the foil pouch may darken with time. Slight darkening will not affect potency, however, product with dark brown contents should be discarded.</span>
</li></ol>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-02.jpg"></p>
<p><span class="Bold">2 Prepare the Medication for Administration</span></p>
<ol class="LittleAlpha">
<li>Shake the bottle well to make sure that the medication is thoroughly mixed.</li>
<li>Remove the protective sheath from the applicator tip. Hold the bottle at the neck so as not to cause any of the medication to be discharged.</li>
</ol>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-03.jpg"><br><br></p>
<p><span class="Bold">3 Assume the Correct Body Position</span></p>
<dl>
<dt class="Bold">a.</dt>
<dd>Best results are obtained by lying on the left side with the left leg extended and the right leg flexed forward for balance.</dd>
</dl>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-04.jpg"></p>
<dl>
<dt class="Bold">b.</dt>
<dd>An alternative to lying on the left side is the "knee-chest" position as shown here.</dd>
</dl>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-05.jpg"><br><br></p>
<p><span class="Bold">4 Administer the Medication</span></p>
<dl>
<dt class="Bold">a.</dt>
<dd>Gently insert the lubricated applicator tip into the rectum to prevent damage to the rectal wall, pointed slightly toward the navel.</dd>
<dt class="Bold">b.</dt>
<dd>Grasp the bottle firmly, then tilt slightly so that the nozzle is aimed toward the back, squeeze slowly to instill the medication. Steady hand pressure will discharge most of the medication. After administering, withdraw and discard the bottle.</dd>
</dl>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-06.jpg"></p>
<dl>
<dt class="Bold">c.</dt>
<dd>Remain in position for at least 30 minutes to allow thorough distribution of the medication internally. Retain the medication all night, if possible.</dd>
</dl>
<p><span class="Bold">Rx</span> only</p>
<p>Rev. 06/08<br>© ALAVEN<span class="Sup">®</span> Pharmaceutical LLC<br>www.sfROWASA.com</p>
<p>Manufactured For:<br><span class="Bold">Alaven<span class="Sup">®</span> Pharmaceutical LLC</span><br>2260 Northwest Parkway, Suite A<br>Marietta, GA 30067</p>
<p>For Medical Inquiries, Call Toll Free:<br>1-888-317-0001</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton</h1>
<p class="First"><span class="Bold Italics">SFROWASA™</span></p>
<p><span class="Italics">(mesalamine)</span></p>
<p><span class="Italics">Rectal Suspension, 4g/60mL</span></p>
<p><span class="Bold Italics">Sulfite-Free Formulation</span></p>
<p>www.sfRowasa.com</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70&amp;name=rowasa-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SF ROWASA 		
					</strong><br><span class="contentTableReg">mesalamine suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68220-022</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Mesalamine</strong> (Mesalamine) </td>
<td class="formItem">Mesalamine</td>
<td class="formItem">4 g  in 60 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carbomer 934</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>petrolatum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68220-022-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68220-022-60</td>
<td class="formItem">60 mL in 1 BOTTLE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68220-022-07</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68220-022-60</td>
<td class="formItem">60 mL in 1 BOTTLE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68220-022-14</td>
<td class="formItem">14  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68220-022-60</td>
<td class="formItem">60 mL in 1 BOTTLE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:68220-022-28</td>
<td class="formItem">28  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:68220-022-60</td>
<td class="formItem">60 mL in 1 BOTTLE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019618</td>
<td class="formItem">09/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alaven Pharmaceutical LLC
							(140210829)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANIP Acquisition Company</td>
<td class="formItem"></td>
<td class="formItem">148515737</td>
<td class="formItem">ANALYSIS, MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2d0c0036-793a-499a-ae56-5d7dcdb62ef2</div>
<div>Set id: a666d21d-da21-498d-aea2-055326cafd70</div>
<div>Version: 2</div>
<div>Effective Time: 20091020</div>
</div>
</div> <div class="DistributorName">Alaven Pharmaceutical LLC</div></p>
</body></html>
